Disclaimer
This program was supported by a non-CME sponsorship grant from Jazz Pharmaceuticals.
Advances in HER2-Targeted Therapy for Advanced and Metastatic Gastroesophageal Adenocarcinoma (GEA)
Faculty
This educational program has been developed with the assistance of:
Professor Wainberg, Professor of Medicine and co-director of the GI Oncology Program at UCL Health and Santa Monica, California.
Disclosures
Faculty Disclosures:
Professor Elimova is a consultant for Jazz/Zymeworks, Adaptimmune, BMS, Astellas, Beigene, ViractaTx, Novartis, Natera, Abbvie, Daiichi-Sankyo and Roche; is a speaker for Jazz/Zymeworks; is on the steering committee for Jazz/Zymeworks and Astrazeneca and receives research funding from Jazz/Zymeworks, BMS, Amgen and Astrazeneca.
Professor Wainburg Dr. Wainberg has served as a consultant or advisor to Abbvie,Alligator, Amgen,Arcus, AstraZeneca,Bayer, BeOne, Bristol Myers Squibb, Daiichi, Ipsen, Janssen, Jazz, Lilly, Merck, Merck,KGaA, Novartis, Revolution Medicine, Phanes and Pfizer; has received institutional research funding from Merck, Novartis, and Plexxikon; and has been reimbursed for travel,accommodations, or other expenses by Amgen, Lilly, and Merck.
This educational activity may include discussions of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). The planners of this activity do not recommend the use of any agent outside its labeled indications.
The information presented is intended solely for educational purposes and does not constitute medical advice. It is not intended to represent the best or only methods or procedures appropriate for the medical situation discussed. Rather, it reflects the approach, views, statements, or opinions of the authors or presenters, which may be helpful or of interest to other healthcare professionals. Responsibility for patient care rests with the healthcare professional, based on their professional license, experience, and knowledge of the individual patient.
For additional information about approved uses—including indications, contraindications, warnings, precautions, and adverse events—please refer to the full prescribing information. Note that product labeling may vary by geographic region. In the United States, full prescribing information is available from the U.S. Food and Drug Administration (www.fda.gov).
This activity is intended for healthcare professionals practicing in the United States. To proceed, please confirm that you are a healthcare professional practicing in the U.S.
